Safety
lymphoma, DLBCL
LYMPHOMA
All patients received at least one dose of mivavotinib and were evaluable for safety. Patients received a median of 2 treatment cycles (range 1–68), and the median treatment duration was 6.8 weeks for all patients with lymphoma and 6.0 weeks for patients with DLBCL. Safety is summarized in 